Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...